Ace polymorphism in colorectal cancer patients of Kashmiri population

Open Colorectal Cancer Journal

Volumn 4, Issue , 2011, Pages 1-5

  Sameer, A Syed ^a   Nissar, Saniya ^a   Bashir, Samina ^a   Bashir, Arif ^a   Siddiqi, Mushtaq A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ACE; Colorectal cancer; Kashmir; Polymorphism

Indexed keywords

ACE GENE; ADULT; AMPLICON; ARTICLE; CASE CONTROL STUDY; CELL ADHESION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; POPULATION RISK; PRIORITY JOURNAL;

EID: 79955068646     PISSN: None     EISSN: 18768202     Source Type: Journal    
DOI: 10.2174/1876820201104010001     Document Type: Article

References (34)

1. Center MM, Jemal A, Smith A, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378.
2. Mir MM, Dar NA, Gochhait S, et al. p53 Mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 2005; 116:62-68.
3. Murtaza I, Mushtaq D, Margoob MA, et al. A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley. World J Gastroenterol 2006; 12: 4033-4037.
4. Sameer AS, Rehman S, Pandith AA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009; 15: 244-252.
5. Sameer AS, Shah ZA, Syeed N, et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in ethnic Kashmiri population. Genet Mol Res 2010; 2: 651-660.
6. Salem AH, Batzer MA. High frequency of the D allele of the angiotensin- converting enzyme gene in Arabic populations. BMC Res Notes 2009; 8: 99.
7. Wang JG, Staessen JA. Genetic polymorphisms in the reninangiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410: 289-302.
8. Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest 2001; 31: 476-488.
9. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006; 98: 1123-1133.
10. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
11. Sakuma T, Hirata RD, Hirata MH: Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals. J Clin Lab Anal 2004; 18: 309-316.
12. Obineche EN, Frossard PM, Bokhari AM. An association study of five genetic loci and left ventricular hypertrophy amongst Gulf Arabs. Hypertens Res 2001; 24: 635-639.
13. Zee RY, Ridker PM, Stampfer MJ, Hennekens CH, Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation 1999; 99: 340-343.
14. Gesang L, Liu G, Cen W, et al. Angiotensin-converting enzyme gene polymorphism and its association with essential hypertension in a Tibetan population. Hypertens Res 2002; 25: 481-485.
15. Kennon B, Petrie JR, Small M, Connell JM. Angiotensinconverting enzyme gene and diabetes mellitus. Diabet Med 1999; 16: 448-458.
16. Nacak M, Nacak I, Sanli M, Ozkur M, Pektaş M, Aynaciog̈lu AS. Association of angiotensin converting enzyme gene insertion/ deletion polymorphism with lung cancer in Turkey. Cancer Genet Cytogenet 2010; 198: 22-26.
17. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-299.
18. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin Iconverting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008; 112: 748-757.
19. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004; 23: 317-329.
20. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I - converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002; 23: 348-356.
21. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294: 441-447.
22. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010; 59: 630-637.
23. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2: 1139-1147.
24. Sierra Díaz E, Sánchez Corona J, Rosales Gómez RC, et al. Angiotensin- converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J Renin Angiotensin Aldosterone Syst 2009; 10: 241-246.
25. Puddefoot JR, Udeozo UK, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer 2006; 13: 895-903.
26. Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 2010; 23: 941-948.
27. Röcken C, Lendeckel U, Dierkes J, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I - converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 2005; 11: 2526-2530.
28. Lang L. ACE inhibitors may reduce esophageal cancer incidence. Gastroenterology 2006; 131: 343-344.
29. Röcken C, Neumann K, Carl-McGrath S, et al. The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 2007; 9: 716-722.
30. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010; 10: 134.
31. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-711.
32. Siddiqi M, Kumar R, Fazili Z, Spiegelhalder B. Increased exposure to dietary amines and nitrate in a population at high risk of zsophageal and gastric cancer in Kashmir (India). Carcinogenesis 1992; 13: 1331-1335.
33. Toma M, Cimponeriu D, Apostol P, et al. Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients. Chirurgia (Bucur) 2009; 104: 553-556.
34. Nikiteas N, Tsigris C, Chatzitheofylaktou A, Yannopoulos A. No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme. In Vivo 2007; 21: 1065-1068.